Newsgroup: it.economia.borsa
Titolo: okkio CELL sta per partire...

okkio.......
poi nun ve lo dico cchiשש... 

 poi nun ve lo dico cchiùù...
so sempre il primo a segnalarla ;o)))))))))))))) incrementato 2.28........

eh eh partita
come previso
è già a 2,32 :-))

 ha scritto nel messaggio 
news:G1Sye.4884$b93...@tornado.fastwebnet.it...


 poi nun ve lo dico cchiùù...
quando arriva a 8 euro? 

 è già a 2,32 :-))
brrr ho l'adrenaliona a millleeeeeeeeeeeeeeeeeeeeeeeeee!!! altro che
d'altonico ahahah ma vienii

poi nun ve lo dico cchiùù... 
A quanto può arrivare in settimana? 2,6? 2,8?

 A quanto puע arrivare in settimana? 2,6? 2,8?
a 1$ 

      Data from XYOTAX(TM) Clinical Program Presented at the 11th World
Conference on Lung Cancer
      Two first-line phase III trials demonstrate a significant
gender-specific survival advantage
      BARCELONA, July 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cell
Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) reported on
presentations of XYOTAX at the International Association for the Study of
Lung Cancer (IASLC) 11th World Conference on Lung Cancer. In an oral session
on advanced lung cancer, results of the STELLAR phase III clinical trials
were presented. In addition, XYOTAX was highlighted in a Symposium and the
pharmacokinetic properties of XYOTAX were highlighted in a poster
presentation.
      In general, results from the phase III studies demonstrated comparable
or superior efficacy, a significant reduction in most taxane-related side
effects, a reduction in requirements for transfusions and growth factors,
and more convenient administration of XYOTAX when compared to the control
arms, which included docetaxel, paclitaxel/carboplatin, and gemcitabine or
vinorelbine. When compared to vinorelbine (32 patients) on the STELLAR 4
trial, XYOTAX patients demonstrated superior survival. In addition, in the
first-line STELLAR 3 and 4 trials in poor performance status (PS2) patients,
XYOTAX demonstrated a statistically significant increase in survival among
women (198 patients total), with a 60 percent increase in 1-year survival.
      "The survival advantage seen in women in the STELLAR 3 and 4 studies
is worthy of note. The trials were stratified by gender and survival by
gender is pre-specified in the analysis plan," stated Scott C. Stromatt,
M.D., Sr. Vice President of Clinical Development and Regulatory Affairs at
CTI. "We plan to explore these results later this summer in our discussions
with FDA regarding the regulatory submission for XYOTAX."
      XYOTAX(TM) (paclitaxel poliglumex, PPX): pharmacokinetic evidence for
prolonged tumor exposure and reduced systemic exposure to paclitaxel
(Abstract 905.00 - Monday, July 4, 2005, 8:00 a.m. CET)
      In a poster presentation, Alberto Bernareggi, M.D., of CTI presented
preclinical and clinical pharmacokinetic results demonstrating that XYOTAX
is stable in systemic circulation, has a low volume of distribution and a
low clearance, accumulates in tumor, and releases paclitaxel progressively,
thus providing prolonged tumor and systemic exposure. These results support
the improved tolerability profile with similar efficacy of XYOTAX compared
to paclitaxel observed in the STELLAR 3 phase III trial in PS2 NSCLC
patients comparing the two drugs in combination with carboplatin.
      Improving outcomes for PS2 patients: Results of the XYOTAX(TM) phase
III STELLAR trials (Symposium - Tuesday, July 5, 2005, 8:00 - 9:30 a.m. CET)
      XYOTAX was featured in a symposium on PS2 NSCLC chaired by Mark Green,
M.D., of Medical University of South Carolina. At the symposium, Kenneth J.
O'Byrne, M.D., of St. James's Hospital, outlined the results in women from
the first-line STELLAR trials. In the 198 women on STELLAR 3 and 4, the
median survival was approximately 9.5 months vs. 7.8 months, 1-year survival
survival was 40% vs. 25%, and 2-year survival was 14% vs. 5% (hazard ratio =
0.70, log rank p-value = 0.03) for women treated with XYOTAX/carboplatin and
XYOTAX as a single-agent compared to women on the control arms
(paclitaxel/carboplatin and gemcitabine or vinorelbine).
      XYOTAX(TM) vs. docetaxel for the second-line treatment of non-small
cell lung cancer (NSCLC): the STELLAR 2 phase III study (Paper #2043.00 -
Wednesday, July 6, 2005, 2:30 - 4:30 p.m. CET)
      Luis Paz-Ares, M.D., of Hospital Doce De Octubre of Madrid, presented
results of the STELLAR 2 clinical trial for the first time in a
peer-reviewed meeting. The trial demonstrated that XYOTAX had similar
efficacy compared to docetaxel, with fewer side effects, except for
neuropathy (all grades, 50 percent for XYOTAX vs. 30 percent for docetaxel),
and fewer severe (grade 3/4) side effects, except for hypersensitivity
reactions (3 percent for XYOTAX vs. <1 percent for docetaxel), resulting in
less supportive care needed by patients on the XYOTAX arm of the study.
Patients on XYOTAX required less epoetin (a substance that stimulates the
bone marrow to make red blood cells), fewer growth factors, and fewer red
blood cell transfusions. XYOTAX was given in a convenient administration
(mean infusion times were 19 minutes vs. 68 minutes for XYOTAX and
docetaxel, respectively) without the requirements for premedications.
Paz-Ares concluded that as a result of the long half-life of XYOTAX, dose
reductions for XYOTAX are recommended for grade 1 neuropathy.
      XYOTAX(TM)/carboplatin vs. paclitaxel/carboplatin for the treatment of
PS2 patients with chemotherapy-naive advanced non-small cell lung cancer
(NSCLC): the STELLAR 3 phase III study (Paper #2051.00 - Wednesday, July 6,
2005, 2:30 - 4:30 p.m. CET)
      Corey J. Langer, M.D., of Fox Chase Cancer Center in Philadelphia,
presented the STELLAR 3 clinical trial results, which were previously
presented at the 2005 Annual Meeting of the American Society of Clinical
Oncology (ASCO). The overall survival for the study was longer than
previously reported for this group of patients, with comparable survival for
both arms of the study. Regional differences were noted in the survival;
patients in the ROW (mostly Eastern European) region had a statistically
significant increase in survival (8.7 month median survival vs. 6.5 months
for the other regions, p<0.001). Severe (grade 3/4) side effects were
comparable on both arms, with more neuropathy and thrombocytopenia seen in
the XYOTAX arm (17 percent vs. 10 percent and 16 percent vs. 4 percent,
respectively). Similar to the STELLAR 2 presentation, Langer concluded that
dose reductions should be recommended for grade 1 neuropathy as a result of
the delayed time to neuropathy experienced by the XYOTAX patients. Mean
administration time for XYOTAX plus carboplatin was 48 minutes compared to 2
24 minutes for paclitaxel plus carboplatin.
      XYOTAX(TM) vs. gemcitabine or vinorelbine for the treatment of
performance status (PS) 2 patients with chemotherapy-naive advanced
non-small cell lung cancer (NSCLC): the STELLAR 4 phase III study (Paper
#2057.00 - Wednesday, July 6, 2005, 2:30 - 4:30 p.m. CET)
      Mary O'Brien, M.D., of Royal Marsden Hospital in London, presented
detailed results of the STELLAR 4 clinical trial for the first time in a
peer- reviewed meeting. The trial demonstrated that XYOTAX had similar
efficacy compared to the control arm (either vinorelbine or gemcitabine),
and the median survival of XYOTAX as a single-agent was similar to
taxane/platinum doublet therapy. In addition, it was noted that women had a
survival advantage, with median survival of 10.4 months, 43 percent 1-year
survival, and 30 percent 2-year survival, compared to 7.0 months, 26 percent
(p = 0.04), and 6 percent (p = 0.02), respectively, for the control arm.
Similar to the STELLAR 2 study, the side effect profile for XYOTAX was
better than the control arm, except for neuropathy (grade 3, 4 percent vs. 0
percent), resulting in significantly less need for supportive care,
including less epoetin, fewer growth factors, and less new opiate use for
patients on the XYOTAX arm. XYOTAX was more convenient to administer (mean
infusion times were 12 minutes vs. 30 minutes for XYOTAX and the control
arm, respectively) and significantly more patients received full course of
therapy compared to the control arm.
      About XYOTAX(TM)
      XYOTAX (paclitaxel poliglumex) is a pharmaceutical that links
paclitaxel, the active ingredient in Taxol(R), to a biodegradable
polyglutamate polymer. This polymer technology results in a new chemical
entity, designed to selectively deliver higher and potentially more
effective levels of active chemotherapeutics to tumors. Blood vessels in
tumor tissue, unlike blood vessels in normal tissue, are porous to molecules
like polyglutamate. Based on preclinical studies, it appears that XYOTAX is
preferentially trapped in the tumor blood vessels allowing significantly
more of the dose of chemotherapy to localize in the tumor. Because more of
the chemotherapy is targeted to the tumor and the levels of chemotherapy
delivered to normal tissue are reduced, XYOTAX may be potentially more
effective and have less severe side effects than currently available
chemotherapeutics.
      About Cell Therapeutics, Inc.
      Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products aimed at making
cancer more treatable. For additional information, please visit
www.cticseattle.com
.
      This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of XYOTAX include risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and with XYOTAX in particular
including, without limitation, the potential failure of XYOTAX to prove safe
and effective or to be approved for use in non-small cell lung and ovarian
cancers, risks that the results of any single STELLAR trial or the body of
data from all 3 STELLAR trials will not be sufficient for FDA to approve
XYOTAX for the treatment of lung cancer, determinations by regulatory,
patent and administrative governmental authorities, competitive factors,
technological developments, costs of developing, producing and selling
XYOTAX, and the risk factors listed or described from time to time in the
Company's filings with the Securities and Exchange Commission including,
without limitation, the Company's most recent filings on Forms 10-K, 8-K,
and 10-Q. CTI is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward- looking statements whether as a
result of new information, future events, or otherwise.
      SOURCE Cell Therapeutics, Inc.


**** mi sta uscendo il sangue dai coglioni tanto li sto grattando...

 **** mi sta uscendo il sangue dai coglioni tanto li sto grattando...
non serve, tanto kiss è come la ely, ce beccasse na vorta (anzi ha sempre 
effetto contrario) guarda invece il sottoscritto : non ho fatto in tempo a 
di "okkio a cell" che è decollata... :-)))